Akso Health Group (AHG) - Form 20-F Summary
Business Context and Reporting Period
Company: Akso Health Group (formerly Xiaobai Maimai Inc., formerly Hexindai Inc.)
Reporting Period: Fiscal Year ended March 31, 2026
Jurisdiction: Cayman Islands (Foreign Private Issuer)
Listing: Nasdaq Capital Market (Symbol: AHG)
Business Overview: The Company has transitioned from its historical P2P lending and social e-commerce businesses (discontinued in 2020 and 2023, respectively) to a focus on healthcare. Current operations include marketing promotion services for the car insurance industry and online healthcare services via the acquisition of Tianjin Wangyi Cloud Co., Ltd. (Deyihui Group). The Company previously engaged in medical device sales but reported nil revenue in this segment for the fiscal year ended March 31, 2026.
Key Financial Metrics
| Metric | Fiscal Year 2026 | Fiscal Year 2025 | Fiscal Year 2024 |
|---|---|---|---|
| Net Revenues | $13.83 million | $14.78 million | $2.41 million |
| Gross Profit | ($0.01) million | ($0.28) million | $0.12 million |
| Net Loss | ($18.72) million | ($135.47) million | ($9.52) million |
| Operating Expenses | $20.69 million | $166.02 million | $8.76 million |
| Impairment Charges | $16.70 million | $162.38 million | $0 |
| Cash and Cash Equivalents (End of Period) | $0.17 million | $176.23 million | $85.17 million |
| Working Capital | $180.84 million | $182.31 million | $138.40 million |
Note: The significant decrease in cash from 2025 to 2026 was primarily due to investing activities related to capital expenditures for Internet Hospital development, which were subsequently refunded (see Material Changes).
Material Changes vs. Prior Period
- Revenue Decline: Net revenues decreased by 6.4% to $13.83 million, driven by a 100% drop in medical device sales (nil revenue in 2026 vs. $0.42 million in 2025) and a 3.7% decline in marketing promotion services.
- Significant Reduction in Loss: Net loss improved significantly to $18.72 million from $135.47 million in the prior year. This improvement is primarily attributable to a $145.7 million decrease in impairment charges on goodwill and intangible assets.
- Impairment Charges:
- 2026: $16.70 million total impairment ($11.1 million goodwill, $5.6 million intangible assets). This followed the termination of development agreements for the Internet Hospital business due to vendor inability to meet specifications and policy uncertainties.
- 2025: $162.38 million total impairment ($41.4 million goodwill, $121.1 million intangible assets) related to the acquisition of Tianjin Wangyi Cloud.
- Cash Position: Cash and cash equivalents dropped from $176.2 million to $0.17 million. However, in June 2026 (subsequent to the balance sheet date), the Company received a full refund of $175.7 million in advance payments for capital expenditures, restoring liquidity.
Guidance, Outlook, and Risks
Outlook and Strategy:
- The Company plans to expand its online hospital and chain pharmacy segments in China, leveraging the Deyihui Group acquisition.
- Future growth strategies include establishing cancer therapy and radiation oncology centers in the U.S., though this remains in the planning/early development stage.
- Management intends to use proceeds from recent private placements and the refunded capital expenditures for working capital and general corporate purposes.
Material Risks and Contingencies:
- Going Concern: The auditor has included an emphasis of matter regarding the Company's ability to continue as a going concern due to accumulated deficits and operating losses, though management believes the recent refund of $175.7 million provides sufficient liquidity for the next 12 months.
- Regulatory Risks (PRC): Significant risks related to PRC regulations on data security, cybersecurity reviews, and foreign investment. The Company operates through a Variable Interest Entity (VIE) structure, which carries legal and operational risks if PRC authorities deem the structure non-compliant.
- HFCA Act: Risk of delisting from U.S. exchanges if the PCAOB is unable to inspect the Company's auditor (CHI-LLTC) for two consecutive years, although the auditor is currently subject to inspection.
- Customer Concentration: High concentration risk; for FY2026, three customers accounted for 63% of total revenue, and one vendor accounted for 100% of marketing promotion purchases.
Investor Verification Checklist
- Liquidity Status: Verify the actual receipt and availability of the $175.7 million refund from vendors mentioned as a subsequent event to confirm the Company's ability to meet short-term obligations.
- Impairment Validity: Review the detailed valuation assumptions used for the $16.7 million impairment charge in 2026, specifically regarding the "zero fair value" conclusion for the Internet Hospital license.
- Revenue Sustainability: Assess the sustainability of the marketing promotion service revenue given the 100% reliance on a single vendor and high customer concentration.
- Regulatory Compliance: Confirm the Company's current status regarding PRC cybersecurity reviews and CSRC filing requirements for overseas listings.
- Internal Controls: Note that the Company remediated material weaknesses in internal controls over financial reporting identified in the prior year, but verify the effectiveness of these new controls.